Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2629
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStaatz, C. E.en
dc.contributor.authorHennig, S.en
dc.contributor.authorLlanos-Paez, C. C.en
dc.contributor.authorLawson, R.en
dc.date.accessioned2022-11-07T23:33:34Z-
dc.date.available2022-11-07T23:33:34Z-
dc.date.issued2020en
dc.identifier.citationJan 27 64, (2), 2020en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/2629-
dc.description.abstractDosing gentamicin in pediatric patients can be difficult due to its narrow therapeutic index. A significantly higher percentage of fat mass has been observed in children receiving oncology treatment than in those who are not. Differences in the pharmacokinetics of gentamicin between oncology and nononcology pediatric patients and individual dosage requirements were evaluated in this study, using normal fat mass (NFM) as a body size descriptor. Data from 423 oncology and 115 nononcology patients were analyzed. Differences in drug disposition were observed between the oncology and nononcology patients, with oncology patients having a 15% lower central volume of distribution and 32% lower intercompartmental clearance. Simulations based on the population pharmacokinetic model demonstrated low exposure target attainment in all individuals at the current clinical recommended starting dose of 7.5 mg/kg of body weight once daily, with 57.4% of oncology and 35.7% of nononcology subjects achieving a peak concentration (C (max)) of ≥25 mg/liter and 64.3% of oncology and 65.6% of nononcology subjects achieving an area under the concentration-time curve at 24 h postdose (AUC(24)) of ≥70 mg · h/liter after the first dose. Based on simulations, the extent of the impact of differences in drug disposition between the two cohorts appeared to be dependent on the exposure target under examination. Greater differences in achieving a C (max) target of >25 mg/liter than an AUC(24) target of ≥70 mg · h/liter between the cohorts was observed. Further investigation into whether differences in the pharmacokinetics of gentamicin between oncology and nononcology patients are a consequence of changes in body composition is required.1098-6596Llanos-Paez, C C <br />Staatz, C E <br />Lawson, R <br />Hennig, S <br />Journal Article <br />Research Support, Non-U.S. Gov't <br />Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01730-19. doi: 10.1128/AAC.01730-19. Print 2020 Jan 27. <br />en
dc.language.isoenen
dc.relation.ispartofAntimicrob Agents Chemotheren
dc.titleDifferences in the Pharmacokinetics of Gentamicin between Oncology and Nononcology Pediatric Patientsen
dc.typeArticleen
dc.identifier.doi10.1128/aac.01730-19en
dc.subject.keywordsFemaleen
dc.subject.keywordsGentamicins/*pharmacokineticsen
dc.subject.keywordsHumansen
dc.subject.keywordsInfanten
dc.subject.keywordsInfections/*drug therapyen
dc.subject.keywordsMaleen
dc.subject.keywordsNeoplasms/*drug therapyen
dc.subject.keywordsBody Weighten
dc.subject.keywords*nonmemen
dc.subject.keywords*body compositionen
dc.subject.keywords*gentamicinen
dc.subject.keywords*normal fat massen
dc.subject.keywords*pediatricsen
dc.subject.keywordsAnti-Bacterial Agents/*pharmacokineticsBody Compositionen
dc.subject.keywordsPediatricsen
dc.subject.keywordsChilden
dc.subject.keywordsChild, Preschoolen
dc.subject.keywordsCohort Studiesen
dc.identifier.risid3251en
item.cerifentitytypePublications-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

44
checked on Apr 17, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.